PUBLICATION
Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (Danio rerio) Model: Involvement of Cholinergic System and Brain Oxidative Stress
- Authors
- Brinza, I., Raey, M.A.E., El-Kashak, W., Eldahshan, O.A., Hritcu, L.
- ID
- ZDB-PUB-220924-27
- Date
- 2022
- Source
- Molecules 27(18): (Journal)
- Registered Authors
- Keywords
- Schenkia spicata, cholinergic function, memory, oxidative stress, scopolamine, sweroside, zebrafish
- MeSH Terms
-
- Acetylcholinesterase/metabolism
- Animals
- Anti-Bacterial Agents/pharmacology
- Antifungal Agents/pharmacology
- Antioxidants/adverse effects
- Brain/metabolism
- Cholinergic Agents/pharmacology
- Galantamine/pharmacology
- Glucose/pharmacology
- Hypnotics and Sedatives/pharmacology
- Imipramine/pharmacology
- Inosine Monophosphate/pharmacology
- Iridoid Glucosides/pharmacology
- Maze Learning
- Memory Disorders/chemically induced
- Memory Disorders/drug therapy
- Memory Disorders/pathology
- Oxidative Stress
- Scopolamine*/adverse effects
- Sugars
- Zebrafish*/metabolism
- PubMed
- 36144637 Full text @ Molecules
Citation
Brinza, I., Raey, M.A.E., El-Kashak, W., Eldahshan, O.A., Hritcu, L. (2022) Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (Danio rerio) Model: Involvement of Cholinergic System and Brain Oxidative Stress. Molecules. 27(18).
Abstract
Sweroside is a secoiridoid glycoside and belongs to a large group of naturally occurring monoterpenes with glucose sugar attached to C-1 in the pyran ring. Sweroside can promote different biological activities such as antifungal, antibacterial, hepatoprotective, gastroprotective, sedative and antitumor, antioxidant, and neuroprotective activities. Zebrafish were given sweroside (12.79, 8.35, and 13.95 nM) by immersion once daily for 8 days, along with scopolamine (Sco, 100 μM) 30 min before the initiation of the behavioral testing to cause anxiety and memory loss. Employing the novel tank diving test (NTT), the Y-maze, and the novel object recognition test (NOR), anxiety-like reactions and memory-related behaviors were assessed. The following seven groups (n = 10 animals per group) were used: control, Sco (100 μM), sweroside treatment (2.79, 8.35, and 13.95 nM), galantamine (GAL, 2.71 μM as the positive control in Y-maze and NOR tests), and imipramine (IMP, 63.11 μM as the positive control in NTT test). Acetylcholinesterase activity (AChE) and the antioxidant condition of the brains were also evaluated. The structure of sweroside isolated from Schenkia spicata was identified. Treatment with sweroside significantly improved the Sco-induced decrease of the cholinergic system activity and brain oxidative stress. These results suggest that sweroside exerts a significant effect on anxiety and cognitive impairment, driven in part by the modulation of the cholinergic system activity and brain antioxidant action.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping